19 results about "Cationic liposome" patented technology

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

This invention discloses a cell preparation targeting bone metastatic tumor cells, its preparation method, and its application, belonging to the field of biomedical technology. The cell preparation comprises senescent neutrophils and drug-loaded cationic liposomes internalized within them. The cationic liposomes encapsulate a STING agonist and a pan-photokinase inhibitor. The preparation method includes: preparing drug-loaded liposomes using a thin-film dispersion-ultrasound method; obtaining senescent neutrophils through in vitro culture of extracted neutrophils; and preparing a senescent neutrophil preparation loaded with liposomes. This invention utilizes the natural bone marrow homing ability of senescent neutrophils to achieve precise targeting of bone metastatic tumor cells, and co-delivers two drugs through liposomes, simultaneously activating anti-tumor immunity and inducing tumor cell apoptosis / autophagy, synergistically treating bone metastases. This system has high drug loading capacity, good encapsulation efficiency, and sustained-release effect, and the preparation process is simple and controllable, providing a new strategy for the treatment of cancer bone metastases.

The application belongs to the technical field of biological medicine, and particularly relates to an N,N-dimethylethylene diamine-thiodiglycolic acid monocholesteryl ester conjugate as well as a preparation method and application thereof. The structural formula of the N,N-dimethylethylene diamine-thiodiglycolic acid monocholesteryl ester conjugate is as follows: first, cholesteryl and thiodiglycolic anhydride are dissolved together, N,N-dimethylaminopyridine is added, and a reflux reaction is performed to obtain thiodiglycolic acid monocholesteryl ester; then, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride is dissolved together, N,N-dimethylethylene diamine is added, and a reaction is performed to obtain a conjugate molecule. The conjugate is blended with lecithin to serve as a cationic liposome. By adjusting the ratio of lecithin and the conjugate, the particle size and potential of the cationic liposome can be adjusted.

The present invention provides a use of a paclitaxel cationic liposome in preparation of a drug for treating advanced solid tumors, a use of the paclitaxel cationic liposome and a system therapeutic drug in preparation of a drug for treating advanced solid tumors, and a method for treating advanced solid tumors. A therapeutically effective amount of paclitaxel cationic liposome is administered to patients with advanced solid tumors, or a therapeutically effective amount of paclitaxel cationic liposome and system therapeutic drug is administered to patients with advanced solid tumors.

This invention belongs to the technical field of functional personal care products, and specifically relates to a highly efficient and stable natural sulfur hot spring bath concentrate formula and its preparation process. The bath concentrate formula, by mass percentage, comprises the following components: 35.0-65.0% sulfur hot spring active concentrate, 0.001-0.01% sodium selenite, 0.1-1.0% sodium thiosulfate, 0.05-0.2% disodium EDTA, 0.5-3.0% cationic liposomes, 0.2-0.8% carrageenan, 0.5-3.0% calcium source, 0.3-2.0% magnesium source, 0.1-0.5% bisabolol, 0.1-0.5% dipotassium glycyrrhizate, 0.2-1.5% citrate-sodium citrate buffer pair, 3.0-8.0% polyol, 0.1-0.3% β-cyclodextrin-encapsulated fragrance, and deionized water to 100%. A liquid bath concentrate was obtained using natural sulfur hot spring water as the water source, which fully retains its active sulfide spectrum and characteristic mineral ions, and can be stored for a long time at normal temperature and pressure. It has the advantages of high stability, high polysulfide content, slow release, and no irritation.

The present application relates to the technical field of hydrogel composite scaffold, in particular to a layer-by-layer self-assembled oxygen-responsive liposome hydrogel composite scaffold and a preparation method, hydrophilic nerve growth factor (GDNF) is encapsulated in the aqueous internal region of the liposome, and low-oxygen-responsive vascular endothelial growth factor (VEGF) plasmid and polyarginine are coated by electrostatic adsorption layer by layer (LBL), so as to construct an intelligent responsive LBL double-drug cationic liposome; subsequently, hyaluronic acid-carboxymethyl cellulose sodium (HA-CMC) hydrogel is introduced to carry the liposome to form a double-drug composite scaffold, so as to enhance the adhesion and local release characteristics of the composite scaffold on the wound surface. In a diabetic animal model, the LBL liposome loaded on the HA / CMC hydrogel can significantly accelerate wound healing, promote collagen deposition, angiogenesis and nerve fiber regeneration, and regulate the polarization of macrophages to the repair phenotype, thereby reducing the inflammatory response and achieving functional tissue repair.

The application discloses a nucleic acid-containing nano-carrier and a preparation method and application thereof, and relates to the technical field of nucleic acid delivery, and specifically discloses a nucleic acid-containing nano-carrier, which comprises a nucleic acid component, a cationic liposome and a stabilizer; the average particle size of the nucleic acid-containing nano-carrier is less than or equal to 400 nm; the Zeta potential of the nucleic acid-containing nano-carrier is-10 mV to-40 mV; and the binding rate of the nucleic acid component and the cationic liposome in the nucleic acid-containing nano-carrier is greater than or equal to 50%. The nucleic acid-containing nano-carrier can effectively load and deliver the nucleic acid component, and in practical application, the nucleic acid component can be guaranteed to have high permeability in the skin, and excellent effects such as low irritation and high stability can also be guaranteed.

This invention provides the application of the LHPP gene in liver cancer immunotherapy and liver cancer immunotherapy drugs. Reagents that promote LHPP gene expression can be used to prepare liver cancer immunotherapy drugs. This invention also provides an mRNA nanomedicine, which is prepared by the following method: [The invention then describes a process involving Meo-PEG-Dlink]. m A PLGA solution, an aqueous solution of LHPP gene mRNA, and a cationic liposome solution were mixed and added dropwise to water under stirring to obtain a nanosolution. The nanosolution was then transferred to an ultrafiltration membrane and centrifuged. This invention is the first to discover that LHPP can participate in the immunotherapy of liver cancer and is associated with the survival prognosis of liver cancer. LHPP enhances STAT1 nuclear translocation by affecting the expression of autophagy-regulated IFNβ, thereby promoting the expression of T cell-related chemokines secreted by liver cancer cells, and ultimately promoting CD8+ expression. + T cell infiltration. Therefore, the LHPP gene can serve as a novel target for immunotherapy of liver cancer. The mRNA nanomedicine described has advantages such as long circulation time in the blood, high accumulation in tumors, rapid mRNA release, and low cost.

The application discloses a kind of surface charge self-adapting nano antibacterial particles and preparation method and application thereof.Preparation method includes that cationic phospholipid molecule AGPDP, photothermal molecule DTTB are dissolved in tetrahydrofuran with heat-sensitive phospholipid dipalmitoyl phosphatidylcholine and cholesterol, are injected into the aqueous solution containing bromelain and mixed, dialysis is carried out to obtain liposome nanoparticle, after the liposome nanoparticle is mixed with acid-sensitive polymer CS-DA, obtain surface charge self-adapting nano antibacterial particles DA-L@DTTB / Bro.Through CS-DA coating cationic liposome, it is negative electric under physiological conditions, realizes long cycle;In infected acidic environment, DA hydrolysis, enhance biological membrane penetration;And unhydrolyzed CS-DA bridge multiple positive liposome and induce self-aggregation, prolong retention time.Photothermal agent DTTB is incorporated into liposome with bromelain, realize photothermal and enzyme therapy synergistic delivery.Under 808 nm laser irradiation, EPS is degraded efficiently, and in vitro MRSA biofilm clearance rate is as high as 99.99%.

This invention relates to the field of nanobubble technology, specifically to a macrophage membrane-modified cationic lipid nanobubble loaded with SHP-1 inhibitor, its preparation method, and its applications. This macrophage membrane-modified cationic lipid nanobubble loaded with SHP-1 inhibitor is constructed by using cationic lipid nanobubbles as the core carrier, electrostatically adsorbing and loading SHP-1 inhibitor, and further modifying it with a macrophage membrane. It not only possesses excellent physicochemical properties, a high cell membrane modification rate, and a high membrane protein retention rate, but also exhibits a high targeted uptake rate of M1 macrophages with an inflammatory phenotype in in vitro models. Furthermore, it promotes lipid efflux from foam cells and demonstrates good biocompatibility.

This invention provides a three-effect valence N This invention relates to acetylgalactosamine cationic liposomes, their preparation methods, and applications, belonging to the field of pharmaceutical technology. The invention prepares trivalent... N Acetylgalactosamine cationic liposome nanoparticles possess advantages such as good structural stability, moderate particle size, narrow particle size distribution, moderate surface charge, and low preparation cost, meeting the requirements for nucleic acid drug delivery carriers. The prepared trivalent... N Acetylgalactosamine cationic liposome nanoparticles can also be used to construct sustained-release drug delivery systems for nucleic acid drugs or as transport carriers for non-nucleic acid drugs.

The application provides a cation-modified PDRN delivery system and a preparation method and application thereof, and comprises cationic lipid-based vesicles and PDRN adsorbed on the surface of the cationic lipid-based vesicles, wherein the cationic lipid-based vesicles are lipid-based vesicles modified with cations on the surface, and are selected from any one of cationic liposomes or cation-modified natural plant vesicles, aiming to realize high encapsulation efficiency, excellent long-term stability, excellent skin permeability and cell uptake efficiency of PDRN, and the process is simple, reproducible, and no toxic organic solvents such as diethyl ether are needed in the whole process, in line with the principle of green chemistry, and easy to carry out large-scale production, and can be widely applied to the preparation of skin repair preparations and anti-aging cosmetics.

This application relates to the biomedical field, specifically to a nucleic acid delivery vector formulation and its application, comprising the following components in molar amounts: HEDMA-Apd-C12 5-12 parts, D-lin-MC3-DMA 31.3-41.3 parts, helper phospholipids 10-28.8 parts, cholesterol 19.2-42.7 parts, and PEG-conjugated lipids 1.5-2 parts. This formulation can encapsulate highly efficient protein-expressing mRNA for the treatment of related defective diseases and achieves specific transfection in serum-free T cell and NK cell systems. Compared with Dlin-MC3-DMA and SM-102 assembled cationic liposome formulations, this formulation shows improved efficacy. This research provides a novel, efficient, and low-toxicity delivery strategy for cell and gene therapy, particularly for serum-free CAR-T manufacturing and the development of mucosal vaccines.

The invention relates to engineered umbilical cord mesenchymal stem cell exosomes (hUCMSC-EVs) loaded with siCCR5, their preparation method, and their use in treating Alzheimer's disease. A lipid membrane is first prepared and dissolved, followed by incorporation of siCCR5 and hUCMSC-EVs. Using a cationic liposome extrusion technique, siCCR5 is efficiently delivered into the exosomes to obtain siCCR5-loaded engineered EVs. The resulting exosomes promote tissue regeneration, repair brain tissue, and modulate the brain microenvironment without causing toxicity. By carrying siCCR5, which targets a specific gene, the engineered EVs exhibit stronger targeted therapeutic effects and enhanced anti-inflammatory activity compared to conventional hUCMSC-EVs, thereby improving Alzheimer's disease progression.

A novel cationic lipid has a structure as represented by general formula (1) and specifically relates to a nitrogen-branched cationic lipid, and a liposome containing the cationic lipid, and a nucleic-acid pharmaceutical composition containing the liposome, a preparation method and application thereof, wherein, the definition of each symbol in the formula (1) is as defined herein. The cationic liposome containing the cationic lipid as represented by formula (1) can improve the loading rate and transport efficiency of nucleic-acid drugs. The formulation of the cationic liposome nucleic-acid pharmaceutical composition has good cell compatibility and higher gene transfection capability, and can improve the treatment and / or prevention effects of nucleic-acid drugs.

The application belongs to the field of biological medicine, and relates to a pH-sensitive cationic liposome for targeted delivery of siRNA and paclitaxel to lung cancer cells and a preparation method and application thereof. 2000 DEPE-PEG is obtained by covalently connecting -Mal through a Michael addition reaction 2000 -YSA and DSPE-PEG 2000 -SS31, the initial liposome is prepared through a film dispersion method, and the liposome loaded with PTX is formed through rotation evaporation, hydration, whole-grain, column filtration, and then the siCXCR2 is compressed through electrostatic combination to obtain the liposome loaded with siCXCR2. The targeted liposome constructed in the application can not only effectively improve the sensitivity of cells to PTX, but also effectively protect siRNA from being degraded, thereby realizing the inhibition of the expression of the cancer-related gene CXCR2, reducing the drug resistance of patients to PTX, and achieving the purpose of enhancing the curative effect.

This invention provides an antibacterial cationic liposome nanoparticle, its preparation method, and its application, belonging to the field of biomedical technology. The preparation method of the antibacterial cationic liposome nanoparticle provided by this invention includes the following steps: (1) preparing an aqueous solution of PTCA and a copper chloride solution, and slowly adding the copper chloride solution dropwise to the PTCA solution; (2) transferring the mixture to a constant temperature water bath, and stirring at 90°C and 300 rpm for 48 hours; the resulting product is centrifuged, washed, and dried to obtain PTCA-Cu. 2+ Nanoparticles; (3) Dissolve lecithin, cholesterol, and DOTAP in a mixed solvent of chloroform and methanol, remove the solvent by rotary evaporation to obtain a transparent lipid membrane, and then add PTCA-Cu 2+ The nanoparticle solution was hydrated at 37°C for 1 hour to obtain cLIp / PTCA-Cu. 2+ Liposomes possess high dispersibility, good stability, and mild reaction conditions, making them a green preparation technology with excellent antibacterial effects.